Samuel Castro

Samuel Castro

Auto-generated profile, based on publicly available information

Samuel Castro

Division of Cardiothoracic Anesthesiology, Stanford University School of Medicine, Stanford, California

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CGCandice R. Gurbatri
Candice R. Gurbatri
ILIoana Lia
Ioana Lia
RVRosa Vincent
Rosa Vincent
CCCourtney Coker
Courtney Coker
SCSamuel Castro
Samuel Castro
TDTal Danino
Tal Danino
An engineered probiotic system locally delivers checkpoint blockade nanobodies to tumors for sustained therapeutic release.

15 August 2020 in Cancer Research
Verified
Journal Article
Closed access
CGCandice Gurbatri
Candice Gurbatri
ILIoana Lia
Ioana Lia
RVRosa Vincent
Rosa Vincent
CCCourtney Coker
Courtney Coker
SCSamuel Castro
Samuel Castro
TDTal Danino
Tal Danino
Checkpoint inhibitors have revolutionized cancer therapy but only work in a subset of patients and can lead to a multitude of toxicities, suggesting the need for more targeted delivery systems. Because of their preferential colonization of tumors, microbes are a natural platform for the local delivery of cancer therapeutics. Here, we engineer a probiotic bacteria system for the controlled production and intratumoral release of nanobodies targeting programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) using a stabilized lysing release mechanism. We used computational modeling coupled with experimental validation of lysis circuit dynamics to determine the optimal genetic circuit parameters for maximal therapeutic efficacy. A single injection of this engineered system demonstrated an enhanced therapeutic response compared to analogous clinically relevant antibodies, resulting in tumor regression in syngeneic mouse models. Supporting the potentiation of a systemic immune response, we observed a relative increase in activated T cells, an abscopal effect, and corresponding increases in systemic T cell memory populations in mice treated with probiotically delivered checkpoint inhibitors. Last, we leveraged the modularity of our platform to achieve enhanced therapeutic efficacy in a poorly immunogenic syngeneic mouse model through effective combinations with a probiotically produced cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). Together, these results demonstrate that our engineered probiotic system bridges synthetic biology and immunology to improve upon checkpoint blockade delivery. Citation Format: Candice Gurbatri, Ioana Lia, Rosa Vincent, Courtney Coker, Samuel Castro, Piper Treuting, Taylor Hinchliffe, Nicholas Arpaia, Tal Danino. Engineered probiotics for local delivery of checkpoint blockade nanobodies [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6248.

1 September 2025 in Academic Medicine
Verified
Journal Article
Closed access
SCSamuel Castro
Samuel Castro

18 September 2025 in Pediatric Anesthesia
Verified
Journal Article
Closed access
EWEllen Y. Wang
Ellen Y. Wang
SCSamuel Castro
Samuel Castro
LZLijin Zhang
Lijin Zhang
MSMan Yee Suen
Man Yee Suen
MPMarc Parris
Marc Parris
TCThomas J. Caruso
Thomas J. Caruso

30 July 2023
Verified
Conference Paper
Open access
PDF file
OZO Zaidat
O Zaidat
YAY Ashouri
Y Ashouri
RSR Starke
R Starke
APA Puri
A Puri
BJbrian jankowitz
brian jankowitz
RLReade De Leacy
Reade De Leacy
Introduction Endovascular treatment for intracranial aneurysms has been evolving. Since the results of the ISAT and BRAT trial were published, multiple advancement of endovascular devices and procedures have occurred. The aim of this study is to share interim results for large aneurysms (> 10 mm) treated within the STERLING registry. Methods The STERLING registry (NCT03642639) is a Prospective, Multi-center, Single Arm Study to Obtain ’Real World’ Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms (Cerenovus, Irvine, CA). The primary endpoint was adequate occlusion rate without retreatment at 12 months measured by Independent Core Lab. Secondary outcome measures were packing density, good functional outcome (mRS 0-2), as well as device-related serious events and retreatment rate within 1-year. Results Among the 450 subjects in the STERLING interim analysis, 44 patients had large aneurysms. Mean (Standard Deviation [SD]) age was 60.6(11.35), and most patients were females (77.3%). Hypertension was prevalent in (59.1%) of the cohort, while half of the cohort were smokers and (13.6%) had a history of SAH. Baseline mRS score was 0 and 1 in 61.4% and 27.3%, respectively. Mean (SD) aneurysm height and width were 11.06 mm (3.78) and 10.67 mm (3.44), respectively. Most aneurysms were in the anterior circulation (84.1%) and (61.9%) were sidewall. Median (IQR) dome to neck ratio was 2.0 (1.70-2.65) and 35 (79.5%) aneurysms had a wide neck. Saccular aneurysm was the most common morphology (86.4%) and (27.3%) were ruptured aneurysms. Most common method of treatment was primary coiling (n=16) followed by coiling+flow diversion (n=12). Mean (SD) packing density was 16.8(8.88). Adequate occlusion on 1-year follow-up was achieved in 86.7% (13/15) and four patients required retreatment within 1-year, resulting in 66.7% (10/15) patients with adequate occlusion without retreatment. There was no occurrence of intraprocedural rupture nor symptomatic intraprocedural thromboembolic events. Clinical outcome was available for unruptured aneurysms for 1 year follow-up and good functional outcome was achieved in 85.7% (12/14). Device related significant adverse events occurred in 1 patient only (2.3%). Conclusion Early results from the STERLING registry for large aneurysms are promising. Adequate occlusion per Independent Core Lab was achieved in 86.7% and retreatment rates were relatively low over 1-year follow-up. A good functional outcome was achieved in 85.7% of patients Disclosures O. Zaidat: 1; C; Stryker, Medtronic, Cerenovus, Penumbra, and Genentech. 2; C; Stryker, Medtronic, Cerenovus, Penumbra, and Neuravi. 4; C; ownership interest in Galaxy Therapeutics LLC;. 6; C; honoraria from Codman,Stryker,Penumbra, Medtronic. serves on the endovascular committee as co-chair for NIH StrokeNet Consortium; has served as an expert witness; had a patent for Ischemic stroke.. Y. Ashouri: None. R. Starke: 2; C; Medtronic Neurovascular, Penumbra, Cerenovus, Abbott.,. A. Puri: 1; C; Stryker Neurovascular, Medtronic, Cerenovus. He has received NIH grants. 2; C; tryker Neurovascular, Medtronic, Cerenovus, Microvention, QApel, Perfuze Medical, Arsenal Medical, Merit Medical Agile, Corindus, Imperative Care. 4; C; InNeuroCo Inc, Galaxy therapeutics, Agile Medical, Perfuze medical and Neurotechnology Investors. B. Jankowitz: None. A. Yoo: 1; C; Medtronic, Cerenovus, Penumbra, Stryker, and Genentech. 2; C; Cerenovus, Penumbra, and Zoll. 6; C; Equity interest in Insera Therapeutics. G. Marnat: None. Z. Kulcsar: None. K. Sugiu: None. S. Jahshan: None. P. Machi: None. G. Pero: None. S. Castro: None. J. Howington,: None. C. Schirmer: None. C. Kilburg: None. C. Chivot: None. F. Al-Mufti: None. V. Da Ros: None. B. Gory: None. T. Yao: 2; C; Medtronic. A. Polifka: None. O. Francois,: None. A. Evans: None. J. Machaj: None. R. De Leacy: 2; C; Imperative Care, Cerenovus, Siemens Healthineers, Penumbra. 6; C; equity in Synchron, Endostream, Q’Apel Medical, Spartan Micro, Vastrax.

19 December 2025 in Anesthesiology
Verified
Journal Article
Closed access
SCSamuel Castro
Samuel Castro
LSLouise Sun
Louise Sun
As cardiovascular patients live longer and undergo increasingly complex procedures, relying solely on mortality as benchmark of success is no longer sufficient. While patient-reported outcomes incorporate quality of life, symptoms, and functional status, they are often clinician-framed, lengthy, and difficult to integrate into routine care. Patient-defined outcomes is a patient-led evolution of this concept that emphasizes priorities such as autonomy and independence and avoiding outcomes deemed so undesirable that patients would sacrifice longevity to prevent them. Disability-free survival and patient-defined adverse cardiovascular and noncardiovascular events are composite patient-defined outcomes codeveloped with patients. Unlike patient-reported outcomes, which can be unwieldy, patient-defined outcomes are interpretable, autonomy-centered endpoints that extend beyond survival and traditional quality-of-life questionnaires. Integrating these measures into cardiac surgical and interventional workflows, especially during preoperative assessment and tailored optimization, helps align care with patient goals. Patient-defined outcomes have the potential to transform perioperative care by shifting the focus from living longer to living better.